Hormonal Changes During Pregnancy

During pregnancy, there are significant hormonal changes that occur in a woman’s body. One of the most notable changes is the increase in concentration of oestriol, which is the least potent of the three oestrogens. Oestrogen plays a crucial role in controlling other hormones such as FSH and LH, stimulating and controlling the growth of the placenta, and promoting the growth of maternal breast tissue in preparation for lactation.

Another hormone that increases during pregnancy is oestradiol, which is approximately 50-fold higher. Oestrone also increases, but oestradiol is more potent as it acts on a wider range of receptors.

On the other hand, LH and FSH are downregulated during pregnancy due to the high levels of oestrogen. The release of FSH is inhibited as follicles do not need to be stimulated during pregnancy.

Misoprostol is a synthetic E1 prostaglandin that can be used for various obstetric purposes, including medical termination of pregnancy, induction of labor, and medical management of miscarriage. It works by inducing contractions in the myometrium to expel the products of conception and ripening and dilating the cervix. However, it can cause side effects such as diarrhea, nausea, vomiting, flatulence, and headaches, and in rare cases, uterine rupture. In the case of a miscarriage, expectant management is the first-line option, but medical or surgical management may be necessary in certain situations. Vaginal misoprostol is the most commonly used medical management, and patients should be informed of the potential risks and given appropriate pain relief and antiemetics. Surgical management is not first-line and carries risks such as perforation of the uterus, failure of the procedure, infection, bleeding, damage to the cervix, and venous thromboembolism. Expectant management should be offered and reviewed after 7-14 days, and if bleeding and pain settle, no further treatment is necessary. Mifepristone, an antiprogesterone medication, should not be used in the management of a missed or incomplete miscarriage.

A woman at 12 weeks gestation is seeking Down syndrome screening. Although her age increases the likelihood of her fetus having Down’s syndrome, it will not affect the initial screening process. The standard screening method involves an ultrasound to evaluate nuchal translucency and serum testing to measure levels of β-human chorionic gonadotropin (β-hCG) and pregnancy-associated plasma protein A (PAPP-A). This combined screening can also detect Edward’s (trisomy 18) and Patau (trisomy 13) syndromes. The triple test, which includes α-fetoprotein, unconjugated oestriol, and β-hCG, is conducted between 15-20 weeks gestation to assess for Down’s syndrome. The quadruple test is also an option for women who have missed the window for combined antenatal screening. A biophysical profile, which evaluates fetal wellbeing through ultrasound detection of heart rate, breathing, movement, tone, and amniotic fluid volume, is used to determine the need for rapid induction of labor.

NICE updated guidelines on antenatal care in 2021, recommending the combined test for screening for Down’s syndrome between 11-13+6 weeks. The test includes nuchal translucency measurement, serum B-HCG, and pregnancy-associated plasma protein A (PAPP-A). The quadruple test is offered between 15-20 weeks for women who book later in pregnancy. Results are interpreted as either a ‘lower chance’ or ‘higher chance’ of chromosomal abnormalities. If a woman receives a ‘higher chance’ result, she may be offered a non-invasive prenatal screening test (NIPT) or a diagnostic test. NIPT analyzes cell-free fetal DNA in the mother’s blood and has high sensitivity and specificity for detecting chromosomal abnormalities. Private companies offer NIPT screening from 10 weeks gestation.

Based on the clinical history provided, it appears that the patient may be suffering from Sheehan’s syndrome. This condition is typically caused by severe postpartum hemorrhage, which can lead to ischemic necrosis of the pituitary gland and subsequent hypopituitarism. Common symptoms of Sheehan’s syndrome include a lack of milk production and amenorrhea following childbirth. Diagnosis is typically made through inadequate prolactin and gonadotropin stimulation tests in patients with a history of severe postpartum hemorrhage. It is important to note that hyperprolactinemia, D2 receptor antagonist medication, and pituitary adenoma are not typically associated with a lack of milk production, but rather with galactorrhea.

Understanding Postpartum Haemorrhage

Postpartum haemorrhage (PPH) is a condition where a woman experiences blood loss of more than 500 ml after giving birth vaginally. It can be classified as primary or secondary. Primary PPH occurs within 24 hours after delivery and is caused by the 4 Ts: tone, trauma, tissue, and thrombin. The most common cause is uterine atony. Risk factors for primary PPH include previous PPH, prolonged labour, pre-eclampsia, increased maternal age, emergency Caesarean section, and placenta praevia.

In managing PPH, it is important to involve senior staff immediately and follow the ABC approach. This includes two peripheral cannulae, lying the woman flat, blood tests, and commencing a warmed crystalloid infusion. Mechanical interventions such as rubbing up the fundus and catheterisation are also done. Medical interventions include IV oxytocin, ergometrine, carboprost, and misoprostol. Surgical options such as intrauterine balloon tamponade, B-Lynch suture, ligation of uterine arteries, and hysterectomy may be considered if medical options fail to control the bleeding.

Secondary PPH occurs between 24 hours to 6 weeks after delivery and is typically due to retained placental tissue or endometritis. It is important to understand the causes and risk factors of PPH to prevent and manage this life-threatening emergency effectively.

Fetal fibronectin (fFN) is a protein that is released from the gestational sac and is associated with early labor if levels are high. However, a positive result does not guarantee premature labor. Obstetric teams can use this information to prepare for the possibility of premature labor by informing neonatal intensive care and administering steroids to aid in neonatal lung maturity. In this case, the patient is at high risk for premature labor and experiencing tightenings, so further monitoring is necessary before discharge.

Antibiotics may be necessary if the patient had spontaneously ruptured her membranes, but in this case, a history of watery discharge without fluid seen on speculum examination and a closed os is not enough to initiate antibiotic therapy. However, swabs and urine cultures should be obtained to screen for infection and treat as appropriate since infection can be a factor in premature labor.

Administering steroids can cause hyperglycemia in diabetics, so blood glucose measurements should be closely monitored. Hyperglycemia in the mother can have adverse effects on the fetus, so hourly blood glucose measurements should be taken, and additional insulin given as needed. If blood glucose levels are difficult to control, a sliding scale should be initiated according to local protocol.

Gestational diabetes is a common medical disorder affecting around 4% of pregnancies. Risk factors include a high BMI, previous gestational diabetes, and family history of diabetes. Screening is done through an oral glucose tolerance test, and diagnostic thresholds have recently been updated. Management includes self-monitoring of blood glucose, diet and exercise advice, and medication if necessary. For pre-existing diabetes, weight loss and insulin are recommended, and tight glycemic control is important. Targets for self-monitoring include fasting glucose of 5.3 mmol/l and 1-2 hour post-meal glucose levels.

The recommended treatment for gestational diabetes is short-acting insulin, not longer-acting subcutaneous insulin. If lifestyle modifications and metformin do not improve the condition, the next step is to provide education on how to dose insulin in accordance with meals and offer short-acting insulin. Glibenclamide and gliclazide are not recommended for use in pregnancy due to the risk of adverse birth outcomes and neonatal hypoglycemia. Prescribing both drugs together or long-acting insulin is also not recommended. Short-acting insulin alone provides better postprandial glucose control and is more flexible in responding to the varying diets of pregnant women.

Gestational diabetes is a common medical disorder affecting around 4% of pregnancies. Risk factors include a high BMI, previous gestational diabetes, and family history of diabetes. Screening is done through an oral glucose tolerance test, and diagnostic thresholds have recently been updated. Management includes self-monitoring of blood glucose, diet and exercise advice, and medication if necessary. For pre-existing diabetes, weight loss and insulin are recommended, and tight glycemic control is important. Targets for self-monitoring include fasting glucose of 5.3 mmol/l and 1-2 hour post-meal glucose levels.

The recommended position for women with cord prolapse is on all fours, with their knees and elbows on the ground. It is important to avoid pushing the cord back in, but to keep it warm and moist. This position helps to prevent compression of the presenting part of the fetus. However, immediate preparations for a caesarian section should also be made. The Trendelenburg position, which involves tilting the head end of the bed downwards, is not recommended for cord prolapse. The Lloyd Davis position, which involves separating the legs, is also not recommended. The McRoberts manoeuvre, which involves hyper-flexing the legs tightly to the abdomen, is used for shoulder dystocia during vaginal delivery and is not appropriate for cord prolapse. The lithotomy position, which involves raising the legs in stirrups, is commonly used in obstetrics and gynaecology but is not recommended for cord prolapse.

Understanding Umbilical Cord Prolapse

Umbilical cord prolapse is a rare but serious complication that can occur during delivery. It happens when the umbilical cord descends ahead of the presenting part of the fetus, which can lead to compression or spasm of the cord. This can cause fetal hypoxia and potentially irreversible damage or death. Certain factors increase the risk of cord prolapse, such as prematurity, multiparity, polyhydramnios, twin pregnancy, cephalopelvic disproportion, and abnormal presentations like breech or transverse lie.

Around half of all cord prolapses occur when the membranes are artificially ruptured. Diagnosis is usually made when the fetal heart rate becomes abnormal and the cord is palpable vaginally or visible beyond the introitus. Cord prolapse is an obstetric emergency that requires immediate management. The presenting part of the fetus may be pushed back into the uterus to avoid compression, and the cord should be kept warm and moist to prevent vasospasm. The patient may be asked to go on all fours or assume the left lateral position until preparations for an immediate caesarian section have been carried out. Tocolytics may be used to reduce uterine contractions, and retrofilling the bladder with saline can help elevate the presenting part. Although caesarian section is the usual first-line method of delivery, an instrumental vaginal delivery may be possible if the cervix is fully dilated and the head is low.

In conclusion, umbilical cord prolapse is a rare but serious complication that requires prompt recognition and management. Understanding the risk factors and appropriate interventions can help reduce the incidence of fetal mortality associated with this condition.

To evaluate a patient with suspected premature rupture of membranes, a thorough medical history should be obtained, including the number of pregnancies. A sterile speculum examination is necessary to check for the accumulation of amniotic fluid in the posterior vaginal vault. Digital examination should be avoided to prevent infection. Serum beta-HCG is not recommended, and the patient should have had previous ultrasound scans and have confirmed her pregnancy by this stage. Ultrasound is the appropriate diagnostic tool if there is no evidence of amniotic fluid pooling in the posterior vaginal vault.

Preterm prelabour rupture of the membranes (PPROM) is a condition that occurs in approximately 2% of pregnancies, but it is responsible for around 40% of preterm deliveries. This condition can lead to various complications, including prematurity, infection, and pulmonary hypoplasia in the fetus, as well as chorioamnionitis in the mother. To confirm PPROM, a sterile speculum examination should be performed to check for pooling of amniotic fluid in the posterior vaginal vault. However, digital examination should be avoided due to the risk of infection. If pooling of fluid is not observed, testing the fluid for placental alpha microglobulin-1 protein (PAMG-1) or insulin-like growth factor binding protein-1 is recommended. Ultrasound may also be useful to show oligohydramnios.

The management of PPROM involves admission and regular observations to ensure that chorioamnionitis is not developing. Oral erythromycin should be given for ten days, and antenatal corticosteroids should be administered to reduce the risk of respiratory distress syndrome. Delivery should be considered at 34 weeks of gestation, but there is a trade-off between an increased risk of maternal chorioamnionitis and a decreased risk of respiratory distress syndrome as the pregnancy progresses. PPROM is a serious condition that requires prompt diagnosis and management to minimize the risk of complications for both the mother and the fetus.

Management of Uterine Hyperstimulation Syndrome and Suspicious CTG in Labor

Uterine hyperstimulation syndrome can lead to a suspicious CTG, which requires prompt management to prevent fetal distress. If the patient presents with uterine hyperstimulation syndrome caused by oxytocin infusion, the first step is to reduce the infusion rate and review the CTG in half an hour. If the CTG shows acute bradycardia or prolonged deceleration for more than three minutes, an emergency Caesarean section should be performed if the patient’s cervix is not fully dilated. Instrumental delivery, in the form of forceps or ventouse, is only indicated under certain circumstances, and the patient must be fully dilated. Increasing the oxytocin infusion rate should be avoided as it exacerbates the symptoms of uterine hyperstimulation. When the CTG is normal, no action is required. Early decelerations occur with uterine contractions and are associated with compression of the fetal head during contraction, leading to vagal nerve stimulation and slowing of the fetal heart rate.

Ultrasound in Pregnancy: Nuchal Scan and Hyperechogenic Bowel

During pregnancy, ultrasound is a common diagnostic tool used to monitor the health and development of the fetus. One type of ultrasound is the nuchal scan, which is typically performed between 11 and 13 weeks of gestation. This scan measures the thickness of the nuchal translucency, or the fluid-filled space at the back of the fetus’s neck. An increased nuchal translucency can be a sign of certain conditions, including Down’s syndrome, congenital heart defects, and abdominal wall defects.

Another ultrasound finding that may indicate a potential health issue is hyperechogenic bowel. This refers to an area of the fetus’s bowel that appears brighter than usual on the ultrasound image. Possible causes of hyperechogenic bowel include cystic fibrosis, Down’s syndrome, and cytomegalovirus infection.

It is important to note that these ultrasound findings do not necessarily mean that the fetus has a health problem. Further testing and evaluation may be needed to confirm a diagnosis and determine the best course of action. Ultrasound is just one tool that healthcare providers use to monitor fetal health and ensure the best possible outcome for both mother and baby.

Treatment for Severe Pre-eclampsia and Eclampsia

The recommended treatment for severe pre-eclampsia or eclampsia is intravenous magnesium sulphate. In addition, antihypertensive treatment is also important, with labetalol being the first line of treatment for hypertension during pregnancy. Nifedipine and methyldopa also have a role to play.

Magnesium sulphate should be administered to patients with severe hypertension and proteinuria, as well as those with mild or moderate hypertension and proteinuria who exhibit symptoms such as severe headache, problems with vision, severe pain just below the ribs or vomiting, papilloedema, signs of clonus, liver tenderness, HELLP syndrome, platelet count falling to below 100 ×109/L, or abnormal liver enzymes.

The administration of magnesium sulphate involves a 4 g loading dose given intravenously over five minutes, followed by an infusion of 1 g/hr for 24 hours. In the event of recurrent seizures, an additional bolus dose of 2-4 g should be given over five minutes.

Overall, the treatment for severe pre-eclampsia and eclampsia involves a combination of intravenous magnesium sulphate and antihypertensive medication, with the dosage and administration of magnesium sulphate varying depending on the patient’s symptoms and condition.

The patient is likely suffering from obstetric cholestasis, which can increase the risk of premature birth and stillbirth. The main symptom is severe itching, and elevated serum bile acids are typically present. Liver function tests, including bilirubin levels, may not be reliable. The most effective treatment is ursodeoxycholic acid (UDCA), which is now mostly synthetic. While antihistamines and topical menthol creams can provide some relief, UDCA is more likely to improve outcomes.

Intrahepatic Cholestasis of Pregnancy: Symptoms and Management

Intrahepatic cholestasis of pregnancy, also known as obstetric cholestasis, is a condition that affects approximately 1% of pregnancies in the UK. It is characterized by intense itching, particularly on the palms, soles, and abdomen, and may also result in clinically detectable jaundice in around 20% of patients. Raised bilirubin levels are seen in over 90% of cases.

The management of intrahepatic cholestasis of pregnancy typically involves induction of labor at 37-38 weeks, although this practice may not be evidence-based. Ursodeoxycholic acid is also widely used, although the evidence base for its effectiveness is not clear. Additionally, vitamin K supplementation may be recommended.

It is important to note that the recurrence rate of intrahepatic cholestasis of pregnancy in subsequent pregnancies is high, ranging from 45-90%. Therefore, close monitoring and management are necessary for women who have experienced this condition in the past.

To screen for postnatal depression, healthcare professionals can use the Edinburgh Scale questionnaire. Patients displaying symptoms of depression after giving birth should be assessed using either the Edinburgh Scale or the PHQ-9 form, according to NICE guidelines. The severity of anxiety can be measured using the GAD 7 questionnaire. The Bishop score is a scoring system used to determine if induction of labor is necessary.

Understanding Postpartum Mental Health Problems

Postpartum mental health problems can range from mild ‘baby-blues’ to severe puerperal psychosis. To screen for depression, healthcare professionals may use the Edinburgh Postnatal Depression Scale, which is a 10-item questionnaire that indicates how the mother has felt over the previous week. A score of more than 13 indicates a ‘depressive illness of varying severity’, with sensitivity and specificity of more than 90%. The questionnaire also includes a question about self-harm.

‘Baby-blues’ is seen in around 60-70% of women and typically occurs 3-7 days following birth. It is more common in primips, and mothers are characteristically anxious, tearful, and irritable. Reassurance and support from healthcare professionals, particularly health visitors, play a key role in managing this condition. Most women with the baby blues will not require specific treatment other than reassurance.

Postnatal depression affects around 10% of women, with most cases starting within a month and typically peaking at 3 months. The features are similar to depression seen in other circumstances, and cognitive behavioural therapy may be beneficial. Certain SSRIs such as sertraline and paroxetine may be used if symptoms are severe. Although these medications are secreted in breast milk, they are not thought to be harmful to the infant.

Puerperal psychosis affects approximately 0.2% of women and requires admission to hospital, ideally in a Mother & Baby Unit. Onset usually occurs within the first 2-3 weeks following birth, and features include severe swings in mood (similar to bipolar disorder) and disordered perception (e.g. auditory hallucinations). There is around a 25-50% risk of recurrence following future pregnancies. Paroxetine is recommended by SIGN because of the low milk/plasma ratio, while fluoxetine is best avoided due to a long half-life.

Hypertension during pregnancy is a common occurrence that requires careful management. In normal pregnancies, blood pressure tends to decrease in the first trimester and then gradually increase to pre-pregnancy levels by term. However, in cases of hypertension during pregnancy, the systolic blood pressure is usually above 140 mmHg or the diastolic blood pressure is above 90 mmHg. Additionally, an increase of more than 30 mmHg systolic or 15 mmHg diastolic from the initial readings may also indicate hypertension.

There are three categories of hypertension during pregnancy: pre-existing hypertension, pregnancy-induced hypertension (PIH), and pre-eclampsia. Pre-existing hypertension refers to a history of hypertension before pregnancy or elevated blood pressure before 20 weeks gestation. PIH occurs in the second half of pregnancy and resolves after birth. Pre-eclampsia is characterized by hypertension and proteinuria, and may also involve edema.

The management of hypertension during pregnancy involves the use of antihypertensive medications such as labetalol, nifedipine, and hydralazine. In cases of pre-existing hypertension, ACE inhibitors and angiotensin II receptor blockers should be stopped immediately and alternative medications should be prescribed. Women who are at high risk of developing pre-eclampsia should take aspirin from 12 weeks until the birth of the baby. It is important to carefully monitor blood pressure and proteinuria levels during pregnancy to ensure the health of both the mother and the baby.

Management of Severe Pre-eclampsia: Medications to Consider and Avoid

Severe pre-eclampsia, characterized by high blood pressure and proteinuria, can lead to eclamptic seizures and other complications. To prevent seizures, magnesium sulphate is administered as a loading dose followed by an infusion. Labetalol is the first-line medication for controlling blood pressure, but nifedipine and methyldopa can be used if labetalol is contraindicated. Ramipril, an ACE inhibitor, and amlodipine, a calcium channel blocker, are not recommended in pregnancy due to their teratogenic effects. Atenolol, a beta blocker, is not the agent of choice for pre-eclampsia management. Aspirin may be given prophylactically to women at risk of pre-eclampsia. Delivery of the fetus is the only definitive treatment for severe pre-eclampsia.

In cases where pregnant women experience severe nausea and vomiting leading to ketonuria and dehydration, admission to the hospital should be considered. This is especially true if they have already tried oral anti-emetics without success. Such symptoms are indicative of hyperemesis gravidarum, which can be confirmed by urine dipstick and increased blood urea levels. While pyridoxine is not recommended by the Royal College of Obstetricians and Gynaecologists (RCOG), ondansetron is effective as a second-line option. However, inpatient treatment is necessary. Gastroscopy is unlikely to be helpful at this stage, even if there is a small amount of blood in the vomit, which is likely due to a Mallory-Weiss tear caused by constant retching. Low K+ levels due to vomiting need to be replaced, and anti-emetics are necessary. Therefore, admission to the hospital for IV fluids, anti-emetics, and a trial of a bland diet is the appropriate course of action.

Hyperemesis gravidarum is an extreme form of nausea and vomiting of pregnancy that occurs in around 1% of pregnancies and is most common between 8 and 12 weeks. It is associated with raised beta hCG levels and can be caused by multiple pregnancies, trophoblastic disease, hyperthyroidism, nulliparity, and obesity. Referral criteria for nausea and vomiting in pregnancy include continued symptoms with ketonuria and/or weight loss, a confirmed or suspected comorbidity, and inability to keep down liquids or oral antiemetics. The diagnosis of hyperemesis gravidarum requires the presence of 5% pre-pregnancy weight loss, dehydration, and electrolyte imbalance. Management includes first-line use of antihistamines and oral cyclizine or promethazine, with second-line options of ondansetron and metoclopramide. Admission may be needed for IV hydration. Complications can include Wernicke’s encephalopathy, Mallory-Weiss tear, central pontine myelinolysis, acute tubular necrosis, and fetal growth issues.

Postnatal Hypertension Management: Guidelines for Discharge and Follow-up

Women who experience hypertension during the postnatal period require careful management to ensure their blood pressure is controlled and any underlying causes are addressed. Here are some guidelines for managing postnatal hypertension:

– Women who are discharged and still hypertensive should have their blood pressure checked every other day in the community until targets are achieved.
– The GP at the 6-week postnatal check should convert all women with chronic hypertension (before pregnancy) back to their pre-pregnancy antihypertensive medication, if not contraindicated in breastfeeding.
– If blood pressure is found to be > 150/100 mmHg in the community, the patient should be referred back to the hospital.
– The blood pressure should be checked at least once every two weeks until the woman discontinues antihypertensive treatment.
– The GP at the 6-week postnatal check should stop antihypertensives in all women who required medical treatment in pregnancy, provided their blood pressure is < 130/80 mmHg.
– If a woman still has a blood pressure of ≤ 160/110 mmHg and proteinuria at the 6-week postnatal appointment, despite medical management, she will require a specialist referral to the hospital for further assessment of the underlying causes of hypertension.

By following these guidelines, healthcare providers can ensure that women with postnatal hypertension receive appropriate care and support to manage their condition effectively.

Referral to a maternal fetal medicine unit is recommended if there are no fetal movements felt by 24 weeks. While most women feel their baby moving around 18-20 weeks, it can range from 16-24 weeks. If there is a lack of fetal movement, it could be due to various reasons, including miscarriages and stillbirth, which can be distressing. Therefore, it is important to check the fetal heartbeat and consider an ultrasound to detect any abnormalities if no fetal movements are felt by 24 weeks.

Understanding Reduced Fetal Movements

Introduction:
Reduced fetal movements can indicate fetal distress and are a response to chronic hypoxia in utero. This can lead to stillbirth and fetal growth restriction. It is believed that placental insufficiency may also be linked to reduced fetal movements.

Physiology:
Quickening is the first onset of fetal movements, which usually occurs between 18-20 weeks gestation and increases until 32 weeks gestation. Multiparous women may experience fetal movements sooner. Fetal movements should not reduce towards the end of pregnancy. There is no established definition for what constitutes reduced fetal movements, but less than 10 movements within 2 hours (in pregnancies past 28 weeks gestation) is an indication for further assessment.

Epidemiology:
Reduced fetal movements affect up to 15% of pregnancies, with 3-5% of pregnant women having recurrent presentations with RFM. Fetal movements should be established by 24 weeks gestation.

Risk factors for reduced fetal movements:
Posture, distraction, placental position, medication, fetal position, body habitus, amniotic fluid volume, and fetal size can all affect fetal movement awareness.

Investigations:
Fetal movements are usually based on maternal perception, but can also be objectively assessed using handheld Doppler or ultrasonography. Investigations are dependent on gestation at onset of RFM. If concern remains, despite normal CTG, urgent (within 24 hours) ultrasound can be used.

Prognosis:
Reduced fetal movements can represent fetal distress, but in 70% of pregnancies with a single episode of reduced fetal movement, there is no onward complication. However, between 40-55% of women who suffer from stillbirth experience reduced fetal movements prior to diagnosis. Recurrent RFM requires further investigations to consider structural or genetic fetal abnormalities.

Recommendations for Feeding Low-Birthweight Infants

Low-birthweight infants, those with a birthweight of less than 2,500 g, should be exclusively breastfed for the first six months of life, according to WHO recommendations. If the mother’s milk is not available, donor human milk should be sought. If that is not possible, standard formula milk can be used. There is no difference in the duration of exclusive breastfeeding between low-birthweight and normal-weight infants. Daily vitamin A supplementation is not currently recommended for low-birthweight infants, but very low-birthweight infants should receive daily supplementation of vitamin D, calcium, and phosphorus. Low-birthweight infants who are able to breastfeed should start as soon as possible after birth, once they are clinically stable.

NICE guidelines recommend 10 antenatal visits for first pregnancies and 7 for subsequent pregnancies if uncomplicated. The purpose of each visit is outlined, including booking visits, scans, screening for Down’s syndrome, routine care for blood pressure and urine, and discussions about labour and birth plans. Rhesus negative women are offered anti-D prophylaxis at 28 and 34 weeks. The guidelines also recommend discussing options for prolonged pregnancy at 41 weeks.